B. B. Fuks

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Berkley A. Lynch, Nathalie Lambeng, Karl Nocka et al. · Proceedings of the National Academy of Sciences · 2004 · 1.6K citations · Full text

New Antiepileptic Drug, Molecular Neuroscience, Antiepileptic Drug Levetiracetam +15

Tic20 and Tic22 Are New Components of the Protein Import Apparatus at the Chloroplast Inner Envelope Membrane

Andrei Kouranov, Xuejun Chen, B. B. Fuks et al. · The Journal of Cell Biology · 1998 · 267 citations · Full text

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties

Michel Gillard, B. B. Fuks, Karine Leclercq et al. · European Journal of Pharmacology · 2011 · 238 citations

Neurophysiology, Medicine, Neurotransmitter +10

Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity

Benoît Kenda, Alain Matagne, Patrice Talaga et al. · Journal of Medicinal Chemistry · 2003 · 222 citations · Full text

New Agents, Drug Target, Pharmaceutical Science +18

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein

Michel Gillard, Pierre Chatelain, B. B. Fuks · European Journal of Pharmacology · 2006 · 146 citations

Synaptic Signaling, Medicine, Synaptic Transmission +10